Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies Journal Article

   


Authors: Park, J. A.; Cheung, N. K. V.
Article Title: Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Abstract: Immune checkpoint inhibitors (ICI) have shown great promise in a wide spectrum of adult solid and hematological malignancies, achieving objective tumor responses and prolonging survival. However, there is limited clinical success amongst pediatric patients. In this review, we summarize the current understanding of ICI and present an up-to-date overview of recent and ongoing clinical trials of ICI in pediatric malignancies. In addition, we will discuss immunologic and clinical difficulties in this young population, as well as future prospects for combination of ICI with other immune-based and conventional treatments. © 2017 Elsevier Ltd
Keywords: immunotherapy; immune checkpoint inhibitor; cytotoxic t lymphocyte antigen-4 (ctla-4); programmed death receptor-1 (pd-1); programmed death-ligand 1 (pd-l1)
Journal Title: Cancer Treatment Reviews
Volume: 58
ISSN: 0305-7372
Publisher: Elsevier Inc.  
Date Published: 2017-07-01
Start Page: 22
End Page: 33
Language: English
DOI: 10.1016/j.ctrv.2017.05.006
PROVIDER: scopus
PUBMED: 28622628
PMCID: PMC5524462
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020725218&doi=10.1016%2fj.ctrv.2017.05.006&partnerID=40&md5=512ddf6f2b5377ddb679ec709654ca8c
Notes: Erratum issued, see DOI: 10.1016/j.ctrv.2017.09.007 -- Review -- Export Date: 3 July 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    650 Cheung
  2. Jeong A Park
    19 Park
Related MSK Work